NCEH1: Key Enzyme in Arylacetamide Metabolism (G57552)

Target Name: NCEH1

NCBI ID: G57552

NCEH1

NCEH1: Key Enzyme in Arylacetamide Metabolism

NCEH1 (Arylacetamide deacetylase-like 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. It is a key enzyme in the metabolism of arylacetamides, a class of compounds that are commonly found in fruits and vegetables.

One of the unique features of NCEH1 is its structure. It is a member of the superfamily of N-acetyltransferases, which are a group of enzymes that are involved in the transfer of acetyl groups to other molecules. These enzymes are widely throughout the cell cycle and are involved in a variety of cellular processes, including the regulation of gene expression, DNA replication, and cell growth.

One of the functions of NCEH1 is its role in the metabolism of arylacetamides. These compounds are commonly found in fruits and vegetables and have been shown to have a variety of health benefits, including anti-inflammatory effects and potential anti-cancer effects. However, the metabolism of arylacetamides can also lead to the formation of toxic metabolites, which can cause harm to the body.

NCEH1 is involved in the metabolism of arylacetamides by catalyzing the transfer of the acetyl group from the substrate to the carbonyl group of the cofactor tyrosine. This process is critical for the structural and functional integrity of the enzyme and is a key step in the metabolism of arylacetamides.

In addition to its role in the metabolism of arylacetamides, NCEH1 has also been shown to play a role in the regulation of cellular processes. For example, studies have shown that NCEH1 is involved in the regulation of cell cycle progression and in the regulation of the expression of genes involved in cell growth and differentiation.

Given its role in the metabolism of arylacetamides and its potential involvement in cellular processes, NCEH1 is an attractive drug target or biomarker for a variety of diseases. For example, the metabolism of arylacetamides has been implicated in the development of a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

In addition to its potential as a drug target or biomarker, NCEH1 is also of interest as a potential therapeutic agent. The metabolism of arylacetamides can be disrupted by small molecules, such as those that inhibit the activity of NCEH1. This suggests that NCEH1 may be a useful target for the development of drugs that are designed to disrupt the metabolism of arylacetamides and potentially have therapeutic effects on a variety of diseases.

Overall, NCEH1 is a protein that is widely expressed in various tissues and is involved in the metabolism of arylacetamides. Its role in this process, as well as its potential as a drug target or biomarker, makes it an attractive target for research into the mechanisms of arylacetamide metabolism and their potential applications in the development of therapeutic agents.

Protein Name: Neutral Cholesterol Ester Hydrolase 1

Functions: Hydrolyzes 2-acetyl monoalkylglycerol ether (1-O-alkyl-2-acetyl-sn-glycerol), the penultimate precursor of the pathway for de novo synthesis of platelet-activating factor (PubMed:17052608). May be responsible for the hydrolysis of cholesterol esters (such as cholesteryl (9Z-octadecenoate)) in macrophages (By similarity). Also involved in organ detoxification by hydrolyzing exogenous organophosphorus compounds (By similarity). May contribute to cancer pathogenesis by promoting tumor cell migration (PubMed:17052608)

The "NCEH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCEH1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets